Endeavour Silver Presents Organic Growth Strategy Anchored by Pitarrilla Project
Bitget2026/11/09 22:15- Endeavour Silver projects 2026 production of 13,700,000–14,300,000 silver-equivalent ounces, up from 11,200,000 ounces in 2025.
- Terronera produced 1,354,759 silver-equivalent ounces in the third quarter of 2026, with all-in sustaining costs of USD 21.81 per ounce.
- Kolpa produced 1,286,070 silver-equivalent ounces in the quarter, with all-in sustaining costs of USD 25.4 per ounce.
- Pitarrilla's planned spending includes USD 48 million in capital expenditures and USD 15 million for a feasibility study.
- Cash stood at USD 287.9 million as of September 30, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
